Saphris asenapine: Additional Phase III data

Additional data from 386 patients in a double-blind Phase III trial showed that Saphris met a secondary endpoint of significantly longer time to treatment discontinuation for any reason vs. placebo (p<0.001). Data were presented at European College of Neuropsychopharmacology in Istanbul. ...